Recent Finacing
Recent Raise
Aptinyx develops orally bioavailable small‑molecule NMDA receptor modulators with a proprietary chemistry and discovery platform, advancing NYX-2925 (neuropathic pain, fibromyalgia) and NYX-783 (PTSD) through trials.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
